About
About Daewon Pharmaceutical Co., Ltd
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Visit company website
5 years, 5 months ago
Daewon Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 87.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Daewon Pharmaceutical Co., Ltd's total revenue sank by 11.2% to $77B since the same quarter in the previous year.
Its net income has dropped by 74.6% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 165.3% to $-2B since the same quarter in the previous year.
Based on the above factors, Daewon Pharmaceutical Co., Ltd gets an overall score of 1/5.